# A First Time in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients

> **NCT02119260** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 61 (actual)

## Conditions studied

- Oedema, Pulmonary

## Interventions

- **DRUG:** GSK2798745 solution
- **DRUG:** GSK2798745 suspension
- **DRUG:** GSK2798745 capsule
- **DRUG:** Placebo solution
- **DRUG:** Placebo suspension
- **DRUG:** Placebo capsule

## Key facts

- **NCT ID:** NCT02119260
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-09
- **Primary completion:** 2016-12-25
- **Final completion:** 2016-12-25
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2018-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02119260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02119260, "A First Time in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02119260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*